TREM2 and melanoma: To investigate whether TREM2+ TAMs impact immunotherapy response, we re-analyzed scRNA-seq data of melanomas treated with ICB therapy and observed that TREM2+ TAMs were significantly enriched in melanomas not responsive to ICB therapy.